Synopsis of recent research by authors named "Constantine S Tam"
- Recent research by Constantine S Tam focuses on novel therapies and treatment strategies for B-cell malignancies, particularly the comparative efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors such as zanubrutinib and ibrutinib, as well as the evaluation of pirtobrutinib in specific patient populations.
- Key findings from his studies include the demonstration that dose reductions of ibrutinib do not compromise treatment efficacy, and the superior efficacy of zanubrutinib over ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL) patients, with evidence supporting patients' improved health-related quality of life and long-term outcomes.
- Additionally, his research highlights significant safety profiles associated with these treatments, including an assessment of bleeding risks with pirtobrutinib, the occurrence of cardiovascular events with zanubrutinib, and long follow-ups showing durable responses from combined venetoclax and ibrutinib therapy in mantle cell lymphoma patients.
